



(11) **EP 2 054 476 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 4, 5, 8, 9, 14, 15, 19, 20
Claims EN 1, 2, 10, 11
- (51) Int Cl.:
C09B 57/00 (2006.01)
- (86) International application number:
PCT/US2007/074255
- (87) International publication number:
WO 2008/014280 (31.01.2008 Gazette 2008/05)
- (48) Corrigendum issued on:
14.03.2012 Bulletin 2012/11
- (45) Date of publication and mention
of the grant of the patent:
29.06.2011 Bulletin 2011/26
- (21) Application number: **07799791.4**
- (22) Date of filing: **24.07.2007**

(54) **FLOURESCENT DYES FOR USE IN GLUCOSE SENSING**

FLUORESZENZFARBSTOFFE ZUR VERWENDUNG BEI DER GLUKOSEERFASSUNG

COLORANTS FLUORESCENTS POUR UNE UTILISATION DANS LA DÉTECTION DU GLUCOSE

- | | |
|--|---|
| <p>(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR</p> <p>(30) Priority: 25.07.2006 US 833081 P</p> <p>(43) Date of publication of application:
06.05.2009 Bulletin 2009/19</p> <p>(73) Proprietor: Glumetrics, Inc.
Irvine, CA 92618 (US)</p> <p>(72) Inventor: SURI, Jeff, T.
Rancho Santa Margarita, CA 92688 (US)</p> <p>(74) Representative: Polypatent
Braunsberger Feld 29
51429 Bergisch Gladbach (DE)</p> | <p>(56) References cited:
US-A1- 2006 083 688</p> <ul style="list-style-type: none">• GAMSEY SOYA ET AL.: "Continuous glucose detection using boronic acid-substituted viologens in fluorescent hydrogels: linker effects and extension to fiber optics" LANGMUIR, ACS, WASHINGTON, DC, US, vol. 22, no. 21, 10 October 2006 (2006-10-10), pages 9067-9074, XP002442273 ISSN: 0743-7463• D. B. CORDES ET AL.: "Topics in Fluorescence Spectroscopy; Vol. 11, Glucose Sensing" 2006, SPRINGER, XP008081136 ISBN: 978-0-387-29571-8 Ch. "Two-component optical sugar sensing using boronic acid-substituted viologens with anionic fluorescent dyes- Modulated quenching with viologens as a method for monosaccharide detection", pages 47-87 page 76, scheme 3.7. |
|--|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 054 476 B9

Description

RELATED APPLICATIONS

5 **[0001]** This application claims the benefit of US Provisional Application No. 60/833,081 filed July 25, 2006 which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

10 Field of the Invention


[0002] Novel fluorescent dyes are disclosed for use in analyte detection.

Description of the Related Art

15 **[0003]** Fluorescent dyes, including 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS) and its derivatives, are known and have been used in analyte detection. See *e.g.*, Gamsey, S. et al. 2006 Langmuir ACS 22:9067-9074; U.S. Patent Nos. 6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. Patent Appl. Nos. 10/456,895 and 11/296,898; each of which is incorporated herein in its entirety by reference thereto.


SUMMARY OF THE INVENTION

25 **[0004]** Fluorescent dyes having the below generic structure are disclosed in accordance with embodiments of the present invention.




40 wherein:

R^2 is




50 R^3 is $-(CH_2)_n-A^+M^+$,
wherein n is 1-4,
wherein A^+ is an anionic group selected from the group consisting of SO_3^- , HPO_3^- , CO_2^- and




, and


wherein M^+ is a cationic group selected from the group consisting of H^+ , an alkali metal ion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , an onium ion and NR_4^+ , wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups; R^4 is



R^5 is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4, and Y is selected from the group consisting of NH and O;

R^6 is selected from the group consisting of NHR^7 , OR^7 and CO_2H ; and

R^7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

[0005] Fluorescent dyes having the below generic structure are disclosed in accordance with preferred embodiments of the present invention.



wherein:

R^3 is $-(CH_2)_n-A^-M^+$,

wherein n is 1-4,


wherein A^- is an anionic group selected from the group consisting of SO_3^- , HPO_3^- , CO_2^- and




, and

wherein M^+ is a cationic group selected from the group consisting of H^+ , an alkali metal ion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , an onium ion and NR_4^+ , wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups;

R^8 is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4;

R⁹ is selected from the group consisting of NHR¹⁰, OR¹⁰ and CO₂H; and


R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

[0006] A fluorescent dye termed HPTS-Cys-MA (or HPTS-TriCys-MA) having the below structure is disclosed in accordance with preferred embodiments of the present invention.




[0007] A glucose sensor is disclosed in accordance with another embodiment of the present invention, comprising the dyes disclosed herein (e.g., HPTS-Cys-MA) and a quencher comprising boronic acid, such as 3,3'-oBBV.

[0008] A first method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:



wherein:


R² is



R³ is -(CH₂)_n-A-M⁺,


wherein n is 1-4,

wherein A⁻ is an anionic group selected from the group consisting of SO₃⁻, HPO₃⁻, CO₂⁻ and




, and


wherein M⁺ is a cationic group selected from the group consisting of H⁺, an alkali metal ion, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, an onium ion and NR₄⁺, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups; R⁴ is



R⁵ is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;

R⁶ is selected from the group consisting of NHR⁷, OR⁷ and CO₂H;

R⁷ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and

Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).


[0009] A second method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of:




wherein n is equal to 1-10, n' is equal to 2-4;
 R^9 is selected from the group consisting of NHR^{10} , OR^{10} and CO_2H ; and

R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.

[0010] A specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making HPTS-CysOB as follows:




and making HPTS-Cys-MA as follows:




[0011] Another specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making:


a) TBCys as follows:




b) Phth acid as follows:



c) Phth MA as follows:




d) AminoCysMA as follows:



and

e) HPTS-Cys-MA as follows:



BRIEF DESCRIPTION OF THE DRAWINGS

[0012]

Figure 1. Stern-Volmer Quenching of HPTS-CysMA/3,3'-oBBV in Solution. Shows the relative emission change (Stern-Volmer curve) upon addition of 3,3'-oBBV indicating the quenching of HPTS-CysMA with 3,3'-oBBV.

Figure 2. Glucose Response of HPTS-CysMA/3,3'-oBBV in Solution. Shows the fluorescence emission measured after addition of glucose to HPTS-CysMA and 3,3'-oBBV.

Figure 3. Fluorescence Spectra of HPTS-CysMA in Hydrogel. Shows fluorescence excitation and emission spectra of a polymer hydrogel comprising HPTS-CysMA.

Figure 4. Time Drive of HPTS-Cys-MA in hydrogel at Different pHs, Em = 532 nm. Shows time drive of HPTS-CysMA in hydrogel at different pH's.

Figure 5. pH profile of HPTS-Cys-MA at two different excitations, Em = 532 nm. Shows pH profile of HPTS-CysMA at two different excitation wavelengths.

Figure 6. Glucose Response of HPTS-CysMA/3,3'-oBBV in hydrogel. Shows the glucose response of HPTS-CysMA/3,3'-oBBV in a hydrogel.

Figure 7 Fluorescence Spectra of HPTS-CysMA and HPTS-LysMA. Shows a comparison of the fluorescence spectra of HPTS-Cys-MA and HPTS-Lys-MA. (1×10^{-5} M); Ex Slit 8 nm, Em Slit 12 nm.

Figure 8 Comparison of Stern-Volmer Quenching Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV, [Dye] = 1×10^{-5} M. Shows a comparison of 3,3'-oBBV Stern-Volmer quenching study using HPTS-Cys-MA and HPTS-Lys-MA.


Figure 9 Comparison of Glucose Modulation Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV; [Dye] = 1×10^{-5} M; Q/D = 150. Shows a comparison glucose modulation using HPTS-Cys-MA and HPTS-Lys-MA with 3,3'-oBBV.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Fluorescent Dyes


[0013] The fluorescent dyes of the invention are derivatives of 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H^+ or any other cation. HPTS exhibits two excitation wavelengths at around 405 nm and around 450 nm, which correspond to the absorption wavelengths of the acid and its conjugate base, respectively. The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. The dyes may be used with a quencher comprising boronic acid, such as 3,3'-oBBV.

[0014] A generic structure of dyes in accordance with preferred embodiments of the present invention is:



wherein:


R^2 is



R^3 is $-(CH_2)_n-A-M^+$,

wherein n is 1-4,


wherein A^- is an anionic group selected from the group consisting of SO_3^- , HPO_3^- , CO_2^- and




, and

wherein M^+ is a cationic group selected from the group consisting of H^+ , an alkali metal ion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , an onium ion and NR_4^+ , wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);


R^4 is



R⁵ is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;

R⁶ is selected from the group consisting of NHR⁷, OR⁷ and CO₂H; and

R⁷ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.

[0015] Another generic structure of dyes in accordance with preferred embodiments of the present invention is:



where:

R³ is $\text{—(CH}_2\text{)}_n\text{—A}^-\text{M}^+$,

wherein n is 1-4,


wherein A⁻ is an anionic group selected from the group consisting of SO₃⁻, HPO₃⁻, CO₂⁻ and




, and

wherein M⁺ is a cationic group selected from the group consisting of H⁺, an alkali metal ion, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, an onium ion and NR₄⁺, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups;


R⁴ is



R⁸ is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4;

R⁹ is selected from the group consisting of NHR¹⁰, OR¹⁰ and CO₂H; and


R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

[0016] The structure of HPTS-Cys-MA is as follows:




[0017] As indicated in the generic structures above, substitutions other than Cys-MA on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. For example, either L or D stereoisomers of cysteic acid may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to HPTS-CysMA shown above, other counterions besides NBu₄⁺ may be used, including positively charged metals, e.g., Na⁺. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc. functional groups.

[0018] For comparison, the structure of HPTS-LysMA is pictured below as follows:




First Method of making the generic class of compounds to which HPTS-Cys-MA belongs

[0019] A first method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:



wherein:


R^2 is



R^3 is $-(CH_2)_n-A-M^+$,


wherein n is 1-4,

wherein A^- is an anionic group selected from the group consisting of SO_3^- , HPO_3^- , CO_2^- and




, and


wherein M^+ is a cationic group selected from the group consisting of N^+ , an alkali metal ion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , an onium ion and NR_4^+ , wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups; R^4 is



R^5 is selected from the group consisting of



and



wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;


R^6 is selected from the group consisting of NHR^7 , OR^7 and CO_2H ;

R^7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and

Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).

Second method of making the generic class of compounds to which HPTS-Cys-MA belongs

[0020] A second method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of:




R⁹ is selected from the group consisting of NHR¹⁰, OR¹⁰ and CO₂H; and

R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.



First Specific Method of Synthesizing HPTS-Cys-MA

[0021] Cysteic acid **1** (0.5 mmols, 94 mg-L stereoisomer was used in this synthesis; however, D stereoisomer may also be used) was treated with an aqueous solution of tetrabutylammonium hydroxide (0.5 mmols, 4 mL of 0.125 M solution) at room temperature (scheme 1). After stirring for 30 min, the solution was lyophilized to give **2** and the residue was dissolved in dichloromethane (2 mL). Triethylamine (0.6 mmols, 61 mg) was added followed by the dropwise addition of HPTS-Cl (0.1 mmols, 52 mg) in dichloromethane (2 mL). The mixture stirred for 18 h at room temperature and was then concentrated *in vacuo*. The residue was dissolved in hot isopropyl alcohol and loaded onto a Biotage SP1 25M silica gel cartridge and eluted with NH₄OH:isopropyl alcohol (1:3) to give HPTS-CysOH as a yellow powder (0.024 mmols, 39 mg, 24%). ¹H NMR (D₂O, 500 MHz) δ 0.85 (t, *J* = 7.4 Hz, 36H), 1.20 (s, *J* = 7.4 Hz, 24H), 1.44 (m, 24H), 2.94 (m, 24H), 3.24 (m, 6H), 4.31 (m, 3H), 8.19 (d, *J* = 16.8 Hz, 2H), 8.36 (d, *J* = 9.0 Hz, 1H), 8.50 (d, *J* = 9.3 Hz, 1H), 8.64 (d, *J* = 9.3 Hz, 1H), 8.71 (d, *J* = 7.1 Hz, 1H), 8.90 (m, 4H), 9.19 (d, *J* = 12.0 Hz, 2H).


Scheme 1



[0022] To a solution of HPTS-CysOH (0.0183 mmols, 30 mg) in DMF (1 mL) was added *N*-ethyl-*N*-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (0.055 mmols, 10.5 mg), 1-hydroxybenzotriazole (HOBT) (0.055 mmols, 7.4 mg), *N,N,N',N'*-tetramethyl-*O*-(1*H*-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) (0.055 mmols, 21 mg), and *N,N'*-diisopropylethylamine (DIEA) (0.183 mmols, 24 mg). After the solution was stirred at room temperature for 20 min, *N*-(3-aminopropyl)methacrylamide hydrochloride was added and the mixture was stirred for 48 h. The reaction mixture was precipitated with acetone:ether (5:1, 10 mL) to give an oily residue. The residue was triturated with acetone (10 mL) and sonicated for 30 min to give HPTS-CysMA as a crude mixture (35 mg of orange powder).

Scheme 2**Second Specific Method of Synthesizing HPTS-Cys-MA**Step 1: Synthesis of TBCys:**[0023]**


[0024] In a 500-mL beaker equipped with a magnetic stirring bar, (L)-Cysteic acid (129.24 mmols, 24.1913 g) was dissolved in H₂O (100 mL) and treated with tetrabutylammonium hydroxide (129.24 mmols, 129.24 mL, 128.59 g of a 1.0 M aqueous solution). The mixture was stirred at room temp for 30 min and then frozen using a low temperature (dry ice/2-propanol) bath. The solid was lyophilized over three days to give a glassy material that was re-dissolved in CH₂Cl₂ (300 mL). The solution was evaporated to dryness in a 500-mL flask to give TBCys as a white foam. Yield: 53.3756 g, 129 mmols, 100 %.

Step 2: Synthesis of Phth acid:**[0025]**

[0026] In a 500-mL flask equipped with a magnetic stirring bar, TBCys (129 mmols, 53.1936 g) was dissolved in CHCl₃ (129 mL), and *N,N*-diisopropylethyl amine (65 mmols, 8.385 g, 11.3 mL) was added followed by phthalic anhydride (129 mmols, 19.10748 g) and 4-angstrom molecular sieves (50 mL); the mixture was refluxed for 48 h. The mixture was filtered through a 600-nL glass fritted funnel and the filtrate was concentrated *in vacuo* and washed with diethyl ether (2 × 100 mL) and dried under reduced pressure to give Phth acid complexed with *N,N*-diisopropylethyl amine. Yield: 70 g, 129 mmols, 100 %. ¹H NMR (CDCl₃, 500 MHz) δ 0.95 (t, *J* = 7.4 Hz, 12H), 1.30 (m, 8H), 1.38 (q, *J* = 7.4 Hz, 8H), 1.61 (m, 8H), 2.96 (q, *J* = 7.4 Hz, 1H), 3.23 (m, 8H), 3.55 (sept, *J* = 6.7, 1H), 3.62 (m, 1H), 3.86 (dd, *J*₁ = 5 Hz, *J*₂ = 9.4 Hz, 1H), 5.3 (dd, *J*₁ = 5.4 Hz, *J*₂ = 1.2 Hz, 1H), 7.65 (q, *J* = 3 Hz, 2H), 7.55 (q, *J* = 3 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 12.0, 13.8, 18.1, 19.8, 24.0, 41.7, 50.4, 51.0, 53.1, 58.7, 123.0, 132.8, 133.52, 167.9, 170.7; HPLC supelcosil LC-8-DB, 5 μm, 150 mm × 4.6 mm, λ = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, R_t = 5.9 min.

Step 3: Synthesis of Phth MA:


[0027]



[0028] In a 250-mL round bottom flask equipped with a magnetic stirring bar, Phth acid (24.9 mmols, 13.46 g) was dissolved in CH_2Cl_2 (85 mL) at 0°C and EDC (27 mmols, 5.157 g), HOBT (27 mmols, 3.645 g), and triethylamine (54 mmols, 5.4 g, 7.5 mL) were added sequentially; the mixture was stirred under nitrogen for 20 min. *N*-(3-Aminopropyl) methacrylamide hydrochloride (27 mmols, 4.806 g) was added and the mixture was allowed to reach room temperature over 2 h and then was stirred for an additional 14 h at room temp. The solution was treated with sat. NaHCO_3 (100 mL) and extracted with CH_2Cl_2 (3×20 mL). The CH_2Cl_2 layer was dried over MgSO_4 and concentrated *in vacuo* to give an orange oil that was loaded onto a Biotage KP-sil 40M cartridge. The material was purified via gradient elution with 5 to 15 % MeOH/ CH_2Cl_2 . The product was isolated as a white foam, yield 72 %. ^1H NMR (CDCl_3 , 500 MHz) δ 0.99 (t, J = 7.4 Hz, 12H), 1.44 (sext, J = 7.4 Hz, 8H), 1.66 (m, 10H), 1.89 (s, 3H), 3.28 (m, 11H), 3.38 (sext, 2H), 3.96 (dd, J_1 = 9 Hz, J_2 = 5.9 Hz, 1H), 5.22 (t, J = 1.4 Hz, 1H), 5.44 (dd, J_1 = 1.9 Hz, J_2 = 9.0 Hz, 1H), 5.69 (s, 1H), 5.91 (t, J = 6.0 Hz, 1H), 7.70 (m, 2H), 7.82 (m, 2H), 9.09 (t, J = 5.8 Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 13.8, 18.7, 19.8, 24.1, 29.1, 36.0, 36.4, 50.5, 53.2, 58.9, 119.6, 123.4, 132.3, 134.0, 140.0, 167.9, 168.5, 169.3; HPLC supelcosil LC-8-DB, 5 μm , 150 mm $\times$ 4.6 mm, λ = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, R_t = 6.6 min.

Step 4: Synthesis of AminoCysMA:


[0029]



[0030] In a 100-mL round bottom flask equipped with a magnetic stirring bar, PhthMA (2.59 mmols, 1.7225 g) was dissolved in ethanol (20 mL) and hydrazine monohydrate (2.59 mmols, 0.130 g, 0.126 mL) was added and the mixture was heated at 80°C for two hours. The solution was cooled to room temperature and CH_2Cl_2 (20 mL) was added. The precipitate that was formed was filtered using a fritted funnel and washed with additional CH_2Cl_2 (10 mL) and the filtrate was concentrated *in vacuo*. The residue was dissolved in CH_2Cl_2 (5 mL) and loaded onto a Biotage KP-NH 40M cartridge and eluted with 1% to 15 % MeOH/ CH_2Cl_2 . The fractions were collected and concentrated *in vacuo* to give aminoCysMA as a colorless oil. Yield: 60 %. ^1H NMR (CD_3OD , 500 MHz) δ 1.03 (t, J = 7.4 Hz, 12H), 1.42 (sext, J = 7.4 Hz, 8H), 1.66 (m, 8H), 1.95 (s, 3H), 2.87 (q, J_1 = 9.4 Hz, J_2 = 4.4 Hz, 1H), 3.23 (m, 10H), 3.81 (dd, J_1 = 3.3 Hz, J_2 = 6.0 Hz, 1H), 5.37 (s, 1H), 5.73 (s, 1H); HPLC supelcosil LC-8-DB, 5 μm , 150 mm $\times$ 4.6 mm, λ = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, R_t = 3.5 min.

Step 5: Synthesis of HPTS-Cys-MA:

[0031]



15 **[0032]** In a 50-mL round bottom flask, AminoCysMA (1.09 mmols, 0.5827 g) was dissolved in CH_2Cl_2 (10 mL) and HPTS-Cl (0.29 mmols, 0.163 g) was added. Triethylamine (1.1 mmols, 0.153 mL) was added and the mixture was stirred at room temperature for 16 h. The red solution was treated with 1 M NaOH (10 mL), stirred for 30 min., and the two layers were separated in a separatory funnel. The orange-aqueous layer was passed through a column of Dowex 50W resin (in the H^+ form) to give a yellow/green solution with a pH = 4 as determined by pH paper. The aqueous solution was then passed through a column of Dowex 50W (in the Na^+ form) to obtain the crude sodium salt of HPTS-CysMA.

20 The solution was adsorbed onto polystyrene-divinylbenzene resin (250 g) and washed with H_2O (5×500 mL). The washings were kept and the adsorbed material was removed from the resin with MeOH (1 L). The MeOH/water extract was evaporated to dryness after multiple co-evaporations with fresh MeOH (4×500 mL) and the residue was re-dissolved in MeOH (0.5 mL). Acetone (15 mL) was added and the precipitate was collected by centrifugation and dried under a stream of argon to give HPTS-Cys-MA as an orange/yellow solid. Additional product was isolated from the washings using the same MeOH-extraction procedure. Yield: 40 %. $^1\text{H-NMR}$ (500 MHz, D_2O , ppm): 1.18-1.09 (m, 6H), 1.76-1.53 (m, 9H), 2.73-2.23 (m, 12H); HPLC supelcosil LC-8-DB, 5 μm , 150 mm $\times$ 4.6 mm, FLD detector, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, $R_1 = 11.6$ min; MALDI-TOF for $\text{C}_{46}\text{H}_{58}\text{N}_9\text{Na}_3\text{O}_{22}\text{S}_6$ $[\text{MH}]^+$: 1350, $[\text{MH}-\text{Na}+\text{H}]^+$: 1328, $[\text{MH}-2\text{Na}+2\text{H}]^+$: 1306, $[\text{MH}-3\text{Na}+3\text{H}]^+$: 1284 (major).

30 Quenchers


[0033] As used herein, the term "quencher" refers to a compound that reduces the emission of a fluorescent dye, e.g., HPTS-Cys-MA, when in its presence.

35 **[0034]** In some embodiments, a quencher moiety provides glucose recognition. Such moieties preferably comprise an aromatic boronic acid. More specifically, the boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen) in which the boronic acid reacts reversibly or irreversibly with glucose in aqueous, organic or combination media to form boronate esters. The extent of the reaction is related to glucose concentration in the medium.

40 **[0035]** Bis-onium salts are prepared from conjugated heterocyclic aromatic dinitrogen compounds. The conjugated heterocyclic aromatic dinitrogen are, e.g., dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes, phenanthrolines, and diazafluorenes. It is understood that all isomers of said conjugated heterocyclic aromatic dinitrogen compounds in which both nitrogens can be substituted are useful in this invention. Boronic acid-substituted viologens and boronic acid-substituted polyviologens are described in detail in co-pending U.S. Application No. 11/671,880; incorporated herein in its entirety by reference thereto.

45 **[0036]** In other embodiments, pyridinium boronic acid quenchers are used in combination with the dyes of the present invention. Pyridinium boronic acid quenchers are described in detail in U.S. Provisional Application No. 60/915,372; incorporated herein in its entirety by reference thereto.

[0037] In one preferred embodiment, 3,3'-oBBV may be used as a quencher moiety. The structure of 3,3'-oBBV is:



Functional Analysis of Dyes

[0038] HPTS-Cys-MA was tested in solution using the fluorimeter to determine how it compares with HPTS-LysMA. Stern-Volmer and glucose response studies were carried out back to back under identical conditions to ensure direct comparison.

Solution Studies

[0039] To a solution of HPTS-CysMA (1×10^{-5} M in pH 7.4 PBS) was added increasing amounts of 3,3'-oBBV (30 mM in MeOH) and the fluorescence emission measured after each addition. **Figure 1** gives the relative emission change (Stern-Volmer curve) upon addition of 3,3'-oBBV indicating the quenching of HPTS-CysMA with 3,3'-oBBV. The fluorimeter settings were as follows: 1% attenuation, ex slit 8 nm, em slit 12 nm, 486 nm ex λ , 537 nm em λ .

[0040] HPTS-CysMA (1×10^{-5} M) and 3,3'-oBBV (3×10^{-3} M) were titrated with a stock solution of glucose (31250 mg/dL) in pH 7.4 PBS and the fluorescence emission measured after each addition of glucose. The relative change upon addition of glucose is given in **Figure 2**.

Polymer Studies

[0041] HPTS-CysMA (1 mg), *N,N'*-dimethylacrylamide (400 mg), *N,N'*-methylenebisacrylamide (8 mg), HCl (10 μ L of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to 1 mL in a volumetric flask. The solution was freeze-pump-thawed ($3\times$), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55°C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and its fluorescence excitation and emission spectra obtained (**Figure 3**).

[0042] The film was tested in a flow cell configuration at various pHs (initially at pH 5.1; changed to pH 5.75, 6.26, 6.5, 6.9; 7.4, 8.02, and then back to pH 7.4) at two different excitation wavelengths (418 nm and 486 nm) and was monitored at one emission wavelength (532 nm) over time (**Figure 4**). The fluorimeter settings were as follows: ex slit 5 nm, em slit 3.5 nm, 515 nm cutoff filter, 418 nm ex λ , 486 nm ex λ , 532 nm em λ . The pH profile is summarized in **Figure 5**.

[0043] HPTS-CysMA (2 mg), 3,3'-oBBV (15 mg), *N,N'*-dimethylacrylamide (400 mg), *N,N'*-methylenebisacrylamide (8 mg), HCl (10 μ L of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to 1 mL in a volumetric flask. The solution was freeze-pump-thawed ($3\times$), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55°C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and was tested in a flow cell configuration with increasing amounts of glucose (0, 50, 100, 200, 400 mg/dL). The relative fluorescence change upon addition of glucose is given in **Figure 6**. The fluorimeter settings were as follows: ex slit 8 nm, em slit 3.5 nm, 515 nm cutoff filter, 486 nm ex λ , 532 nm em λ .

Comparison Studies

[0044] A comparison of the fluorescence spectra of the CysMA and LysMA dyes in solution is shown in **Figure 7**. The CysMA dye is blue-shifted relative to the LysMA dye.

[0045] A comparison of the Stern-Volmer quenching study for CysMA and LysMA in solution is given in **Figure 8** and the glucose response is given in **Figure 9**.

[0046] HPTS-CysMA is quenched more effectively with 3,3'-oBBV than is HPTS-LysMA. HPTS-CysMA forms a stronger complex because of the sulfonic acids than does HPTS-LysMA, which has carboxylic acids; the tighter complex leads to a greater glucose response. For this reason, dyes substituted with sulfonate groups are preferred.

Glucose Sensors

[0047] In one preferred embodiment, a device is disclosed for determining blood glucose concentration. The device comprises a sensor comprising an optical fiber sized for deployment intravascularly. The sensor further comprises a water-insoluble polymer matrix, wherein the polymer matrix is permeable to glucose; a fluorescent dye, as disclosed herein, associated with the polymer matrix; a quencher as disclosed herein, adapted to reversibly bind an amount of glucose related to the blood glucose concentration, wherein the quencher is also associated with the polymer matrix and operably coupled to the fluorescent dye, and wherein the quencher is configured to modulate the light emitted by the fluorescent dye related to the amount of bound glucose; at least one excitation light source; and an emission light detector.

[0048] A method is also disclosed for determining blood glucose concentration. The method comprises the steps of: providing the device described above; inserting the sensor into a blood vessel; irradiating the sensor at an excitation wavelength; detecting a fluorescence emission of the sensor at an emission wavelength; and determining the blood glucose concentration.

[0049] In some embodiments, for use *in vitro* not involving a moving stream, the sensing components are used as individual (discrete) components. The dye and quencher are mixed together in liquid solution, analyte is added, the change in fluorescence intensity is measured, and the components are discarded. Polymeric matrices that can be used to trap the sensing components to prevent leaching need not be present. Optionally, the sensing components are immobilized which allows their use to measure analytes in a moving stream.


[0050] For *in vivo* applications, the sensor is used in a moving stream of physiological fluid, preferably blood, which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor assembly. Thus, for use *in vivo*, the sensing components are preferably part of an organic polymer sensing assembly. Soluble dyes and quenchers can be confined by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using soluble sensing moieties that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selectively semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific molecular weight cutoff between the two so that the sensing moieties are quantitatively retained.

[0051] Preferably the sensing moieties are immobilized in an insoluble polymer matrix, which is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer, and/or a semipermeable membrane, that is permeable to the analytes of interest.

[0052] The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effect, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. In some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix must not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels are established in the art. All useful matrices are defined as being analyte permeable.


Claims

1. The compound:



wherein:

R^2 is



R^3 is $-(CH_2)_n-A^+M^+$,

wherein n is 1-4,


wherein A^- is an anionic group selected from the group consisting of SO_3^- , HPO_3^- , CO_2^- and




, and

wherein M^+ is a cationic group selected from the group consisting of H^+ , an alkali metal ion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , an onium ion and NR_4^+ , wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups;


R^4 is



R^5 is selected from the group consisting of




and



wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O ;

R⁶ is selected from the group consisting of NHR⁷, OR⁷ and CO₂H; and
R⁷ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

2. The compound:



wherein:


R³ is -(CH₂)_n-A⁻M⁺,
wherein n is 1-4,
wherein A⁻ is an anionic group selected from the group consisting of SO₃⁻, HPO₃⁻, CO₂⁻ and




, and

wherein M⁺ is a cationic group selected from the group consisting of H⁺, an alkali metal ion, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, an onium ion and NR₄⁺, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups;


R⁴ is



R⁸ is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4;

R⁹ is selected from the group consisting of NHR¹⁰, OR¹⁰ and CO₂H; and

R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

3. The compound of Claim 2, wherein the compound is:



4. The compound of Claim 3, wherein NBu₄ is any other counterion.

5. The compound of Claim 3, comprising L, D, or L and D stereoisomers of cysteine.


6. A glucose sensor comprising the compound of Claim 1.

7. The glucose sensor of Claim 6, further comprising a quencher moiety.

8. The glucose sensor of Claim 7, wherein said quencher moiety comprises boronic acid.


9. The glucose sensor of Claim 8, wherein said boronic acid quencher is 3,3'-oBBV.

10. A method of making the compound of Claim 1, comprising the steps of:



wherein:

R² is



R³ is -(CH₂)_n-A⁺M⁺,
wherein n is 1-4,


wherein A⁻ is an anionic group selected from the group consisting of SO₃⁻, HPO₃⁻, CO₂⁻ and




, and

wherein M⁺ is a cationic group selected from the group consisting of H⁺, an alkali metal ion, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, an onium ion and NR₄⁺, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups;


R⁴ is



R⁵ is selected from the group consisting of



and




wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;

R⁶ is selected from the group consisting of NHR⁷, OR⁷ and CO₂H;

R⁷ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido; and

Z is an amino protecting group selected from the group consisting of Phthalimido, Boc and Fmoc.

11. A method of making the compound of Claim 2, comprising the steps of:




wherein n is equal to 1-10, n' is equal to 2-4;


R^9 is selected from the group consisting of NHR^{10} , OR^{10} and CO_2H ; and

R¹⁰ is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.

12. A method of making the compound of Claim 3, comprising the steps of making HPTS-CysOH as follows; and




making HPTS-Cys-MA as follows:




13. A method of making the compound of Claim 3, comprising the steps of:


making TBCys as follows:




making Phth acid as follows:




making Phth MA as follows:



making AminoCysMA as follows:




and
making HPTS-Cys-MA as follows:




Patentansprüche

1. Die Verbindung:



worin:

R^2 gleich




ist;

R^3 gleich $-(CH_2)_n-A^+M^+$ ist,


worin n gleich 1-4 ist,

wobei A^- eine anionische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus SO_3^- , HPO_3^- , CO_2^- und




und wobei M^+ eine kationische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus H^+ , einem Alkalimetallion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , einem Oniumion und NR_4^+ , wobei R ausgewählt ist aus der Gruppe, bestehend aus Alkyl-, Alkylaryl- und aromatischen Gruppen;

R^4 gleich




ist;

R^5 ausgewählt ist aus der Gruppe bestehend aus




und




worin n gleich 1-10 ist, n' gleich 2-4 ist und Y ausgewählt ist aus der Gruppe, bestehend aus NH und O;
 R⁶ ausgewählt ist aus der Gruppe, bestehend aus NHR⁷, OR⁷ und CO₂H, und
 R⁷ gleich H oder eine ethylenisch ungesättigte Gruppe ist, ausgewählt aus der Gruppe, bestehend aus Me-
 thacryloyl, Acryloyl, Styryl, Acrylamido und Methacrylamido.

2. Die Verbindung:




worin:


R³ gleich $-(CH_2)_n-A-M^+$ ist,
 worin n gleich 1-4 ist,
 wobei A⁻ eine anionische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus SO₃⁻, HPO₃⁻, CO₂⁻ und




und wobei M⁺ eine kationische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus H⁺, einem Alkalimetallion, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, einem Oniumion und NR₄⁺, wobei R ausgewählt ist aus der Gruppe, bestehend aus Alkyl-, Alkylaryl- und aromatischen Gruppen;
 R⁴ gleich



ist;
 R⁶ ausgewählt ist aus der Gruppe, bestehend aus



und




worin n gleich 1-10 ist, n' gleich 2-4 ist;

R^9 ausgewählt ist aus der Gruppe, bestehend aus NHR^{10} , OR^{10} und CO_2H , und

R^{10} gleich H oder eine ethylenisch ungesättigte Gruppe ist, ausgewählt aus der Gruppe, bestehend aus Methacryloyl, Acryloyl, Styryl, Acrylamido und Methacrylamido.

3. Die Verbindung gemäß Anspruch 2, wobei die Verbindung:



darstellt.

4. Die Verbindung gemäß Anspruch 3, worin NBu_4 irgendein anderes Gegenion ist.

5. Die Verbindung gemäß Anspruch 3, umfassend L-, D- oder L- und D-Stereoisomere von Cystein.


6. Ein Glucosesensor, enthaltend die Verbindung gemäß Anspruch 1.

7. Der Glucosesensor gemäß Anspruch 6, außerdem enthaltend eine Quenchereinheit.

8. Der Glucosesensor gemäß Anspruch 7, wobei die Quenchereinheit Borsäure umfasst.


9. Der Glucosesensor gemäß Anspruch 8, wobei der Borsäurequencher 3,3'-oBBV ist.

10. Das Verfahren zur Herstellung der Verbindung gemäß Anspruch 1, umfassend die Schritte:



wobei:

R^2 gleich




ist;

R^3 gleich $-(CH_2)_n-A-M^+$ ist,


worin n gleich 1-4 ist,

wobei A^- eine anionische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus SO_3^- , HPO_3^- , CO_2^- und




und wobei M^+ eine kationische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus H^+ , einem Alkalimetallion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , einem Oniumion und NR_4^+ , wobei R ausgewählt ist aus der Gruppe, bestehend aus Alkyl-, Alkylaryl- und aromatischen Gruppen;

R^4 gleich




ist;

R^5 ausgewählt ist aus der Gruppe bestehend aus



und




worin n gleich 1-10 ist, n' gleich 2-4 ist und Y ausgewählt ist aus der Gruppe, bestehend aus NH und O ;

R^6 ausgewählt ist aus der Gruppe, bestehend aus NHR^7 , OR^7 und CO_2H ;

R^7 gleich H oder eine ethylenisch ungesättigte Gruppe ist, ausgewählt aus der Gruppe, bestehend aus Methacryloyl, Acryloyl, Styryl, Acrylamido und Methacrylamido, und


Z eine Aminoschutzgruppe darstellt, ausgewählt aus der Gruppe bestehend aus Phthalimido, Boc und Fmoc.

11. Ein Verfahren zum Herstellen der Verbindung gemäß Anspruch 1, umfassend die Schritte:




wobei:


R³ gleich -(CH₂)_n-A-M⁺ ist,
 worin n gleich 1-4 ist,
 wobei A⁻ eine anionische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus SO₃⁻, HPO₃⁻, CO₂⁻ und



und wobei M^+ eine kationische Gruppe ist, ausgewählt aus der Gruppe, bestehend aus H^+ , einem Alkalimetallion, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , einem Oniumion und NR_4^+ , wobei R ausgewählt ist aus der Gruppe, bestehend aus Alkyl-, Alkylaryl- und aromatischen Gruppen;
 R^8 ausgewählt ist aus der Gruppe, bestehend aus




und




worin n gleich 1-10 ist, n' gleich 2-4 ist;
R⁹ ausgewählt ist aus der Gruppe, bestehend aus NHR¹⁰, OR¹⁰ und CO₂H, und

R¹⁰ gleich H oder eine ethylenisch ungesättigte Gruppe ist, ausgewählt aus der Gruppe, bestehend aus Methacryloyl, Acryloyl, Styryl, Acrylamido und Methacrylamido.

12. Ein Verfahren zum Herstellen der Verbindung gemäß Anspruch 3, umfassend die Schritte zur Herstellung von HPTS-CysOH wie folgt




und Herstellen von HPTS-Cys-MA wie folgt:




13. Ein Verfahren zum Herstellen der Verbindung gemäß Anspruch 3, umfassend die Schritte:


Herstellen von TBCys wie folgt:




Herstellen der Phtalsäure wie folgt:




Herstellen von Phth MA wie folgt:



und
Herstellen von AminoCysMA wie folgt:




und
Herstellen von HPTS-Cys-MA wie folgt:




Revendications

1. Composé :




dans lequel
R² est



R³ est $-(CH_2)_n-A^+M^+$

où n vaut 1 à 4,


où A⁻ est un groupe anionique choisi dans le groupe constitué par SO₃⁻, HPO₃⁻, CO₂⁻ et




et

où M⁺ est un groupe cationique choisi dans le groupe constitué par H⁺, un ion de métal alcalin, Li⁺, Na⁺, K⁺, Rb⁺, Cs⁺, Fr⁺, un ion onium et NR₄⁺, où R est choisi dans le groupe constitué par les groupes alkyle, alkylaryle et aromatiques ;

R⁴ est



R⁵ est choisi dans le groupe constitué par Y-(CH₂)_n-R⁶ et




où n est égal à 1 à 10, n'est égal à 2 à 4 et Y est choisi dans le groupe constitué par NH et O ;

R⁶ est choisi dans le groupe constitué par NHR⁷, OR⁷ et CO₂H; et

R⁷ est H ou un groupe éthyléniquement insaturé choisi dans le groupe constitué par un groupe méthacryloyle, acryloyle, styryle, acrylamido et méthacrylamido.

2. Composé :



dans lequel

R^3 est $-(CH_2)_n-A-M^+$,

où n vaut 1 à 4,


où A^- est un groupe anionique choisi dans le groupe constitué par SO_3^- , HPO_3^- , CO_2^- et




et

où M^+ est un groupe cationique choisi dans le groupe constitué par H^+ , un ion de métal alcalin, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , un ion onium et NR_4^+ , où R est choisi dans le groupe constitué par les groupes alkyle, alkylaryle et aromatiques ;

R^4 est



R^8 est choisi dans le groupe constitué par $-(CH_2)_n-R^9$ et




où n est égal à 1 à 10, n' est égal à 2 à 4 ;


R^9 est choisi dans le groupe constitué par NHR^{10} , OR^{10} et CO_2H ; et

R^{10} est H ou un groupe éthyléniquement insaturé choisi dans le groupe constitué par un groupe méthacryloyle, acryloyle, styryle, acrylamido et méthacrylamido.

3. Composé selon la revendication 2, dans lequel le composé est :




4. Composé selon la revendication 3, dans lequel NBu_4 est tout autre contre-ion.
5. Composé selon la revendication 3, comprenant les stéréoisomères L, D, ou L et D de la cystéine.
6. Capteur de glucose comprenant le composé de la revendication 1.
7. Capteur de glucose selon la revendication 6, comprenant en outre un fragment extincteur.
8. Capteur de glucose selon la revendication 7, dans lequel ledit fragment extincteur comprend de l'acide boronique.
9. Capteur de glucose selon la revendication 8, dans lequel ledit extincteur acide boronique est le 3,3'-oBBV.
10. Procédé de préparation du composé de la revendication 1, comprenant les étapes suivantes :



où :

R^2 est




R^3 est $-(\text{CH}_2)_n-\text{A}^-\text{M}^+$,
où n vaut 1 à 4,
où A^- est un groupe anionique choisi dans le
groupe constitué par SO_3^- , HPO_3^- , CO_2^- et




et

où M^+ est un groupe cationique choisi dans le groupe constitué par H^+ , un ion de métal alcalin, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , un ion onium et NR_4^+ , où R est choisi dans le groupe constitué par les groupes alkyle, alkylaryle et aromatiques ;

R^4 est



R^5 est choisi dans le groupe constitué par $Y-(CH_2)_n-R^6$ et




où n est égal à 1 à 10, n' est égal à 2 à 4 et Y est choisi dans le groupe constitué par NH et O ;

R^6 est choisi dans le groupe constitué par NHR^7 , OR^7 et CO_2H ;

R^7 est H ou un groupe éthyléniquement insaturé choisi dans le groupe constitué par un groupe méthacryloyle, acryloyle, styryle, acrylamido et méthacrylamido ; et

Z est un groupe protecteur d'amino choisi dans le groupe constitué par phthalimido, Boc et Fmoc.

11. Procédé de préparation du composé de la revendication 2, comprenant les étapes suivantes :



où :

R^3 est $-(CH_2)_n-A^+M^+$,

où n vaut 1 à 4,


où A^- est un groupe anionique choisi dans le groupe constitué par SO_3^- , HPO_3^- , CO_2^- et



et

où M^+ est un groupe cationique choisi dans le groupe constitué par H^+ , un ion de métal alcalin, Li^+ , Na^+ , K^+ , Rb^+ , Cs^+ , Fr^+ , un ion onium et NR_4^+ , où R est choisi dans le groupe constitué par les groupes alkyle, alkylaryle et aromatiques ;

R^8 est choisi dans le groupe constitué par $-(CH_2)_n-R^9$ et




où n est égal à 1 à 10, n' est égal à 2 à 4 ;


R^9 est choisi dans le groupe constitué par NHR^{10} , OR^{10} et CO_2H ; et

R^{10} est H ou un groupe éthyléniquement insaturé choisi dans le groupe constitué par un groupe méthacryloyle, acryloyle, styryle, acrylamido et méthacrylamido.

12. Procédé de préparation du composé de la revendication 3, comprenant les étapes de préparation de HPTS-CysOH comme suit :




et de préparation de HPTS-Cys-MA comme suit :




13. Procédé de préparation du composé de la revendication 3, comprenant les étapes consistant à :


préparer du TBCys comme suit :




préparer de l'acide Phth comme suit :




préparer du Phth MA comme suit :



préparer de l'aminoCysMA comme suit :



et
préparer du HPTS-Cys-MA comme suit :






Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60833081 B [0001]
- US 6653141 B [0003]
- US 6627177 B [0003]
- US 5512246 A [0003]
- US 5137833 A [0003]
- US 6800451 B [0003]
- US 6794195 B [0003]
- US 6804544 B [0003]
- US 6002954 A [0003]
- US 6319540 B [0003]
- US 6766183 B [0003]
- US 5503770 A [0003]
- US 5763238 A [0003]
- US 456895 A [0003]
- US 11296898 A [0003]
- US 671880 A [0035]
- US 915372 P [0036]

Non-patent literature cited in the description

- **Gamsey, S. et al.** *Langmuir ACS*, 2006, vol. 22, 9067-9074 [0003]